The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified September 2012 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Arnon Goldberg, Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01686048
First received: September 12, 2012
Last updated: September 14, 2012
Last verified: September 2012
  Purpose

Ambrosia is known for its allergenicity in the USA causing hay fever and asthma. Israel has always been considered "clean" of Ambrosia but over the past years growth of Ambrosia plants has been detected in several locations in Israel.

In the proposed study, patients referred for routine allergic evaluation will also be skin tested with Ambrosia allergens, in addition to their regular prick skin tests with all other airborne allergens.


Condition
Allergic Rhinitis
Asthma
Allergic Conjunctivitis
Atopic Dermatitis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Estimated Enrollment: 120
Study Start Date: November 2012
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients refered for allergic evaluation

Criteria

Inclusion Criteria:

  • Patients with allergic rhinitis, asthma, allergic conjunctivitis or atopic dermatitis who undergo prick skin tests with airborne allergens
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01686048

Contacts
Contact: Arnon Goldberg, M.D. 972-9-7472717 arnong@clalit.org.il

Locations
Israel
Arnon Goldberg, M.D., Allergy and Clinical Immunology Unit, Meir Medical Center Not yet recruiting
Kfar-Saba, Israel, 44281
Contact: Ronit Confino-Cohen, M.D.    972-9-7472811    ronitco@clalit.org.il   
Sponsors and Collaborators
Meir Medical Center
  More Information

No publications provided

Responsible Party: Arnon Goldberg, Head, Allergy and Clinical Immunology Unit, Meir Medical Center
ClinicalTrials.gov Identifier: NCT01686048     History of Changes
Other Study ID Numbers: Ambrosia
Study First Received: September 12, 2012
Last Updated: September 14, 2012
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Conjunctivitis
Conjunctivitis, Allergic
Asthma
Dermatitis
Dermatitis, Atopic
Rhinitis
Rhinitis, Allergic, Perennial
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Conjunctival Diseases
Eye Diseases
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Nose Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases

ClinicalTrials.gov processed this record on August 28, 2014